Bone Biologics Financials
This page shows Bone Biologics (bblgw) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 20 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Bone Biologics passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Bone Biologics generates $1.00 in operating cash flow (-$4.1M OCF vs -$4.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Bone Biologics reported -$4.1M in net income in fiscal year 2024. This represents an increase of 54.0% from the prior year.
Bone Biologics earned $-4.83 per diluted share (EPS) in fiscal year 2024. This represents an increase of 85.8% from the prior year.
Bone Biologics held $3.3M in cash against $0 in long-term debt as of fiscal year 2024.
Bone Biologics had 492,417 shares outstanding in fiscal year 2024. This represents a decrease of 7.8% from the prior year.
Bone Biologics invested $2.1M in research and development in fiscal year 2024. This represents a decrease of 69.2% from the prior year.
bblgw Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $188K-56.3% | $430K | N/A | $1.6M | N/A | $769K | N/A | $2K |
| SG&A Expenses | $527K+1.2% | $521K | N/A | $506K | N/A | $450K | N/A | $230K |
| Operating Income | -$715K+24.8% | -$951K | N/A | -$2.1M | N/A | -$1.2M | N/A | -$230K |
| Interest Expense | N/A | $255 | N/A | $536 | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $33K | N/A | N/A |
| Net Income | -$667K+29.1% | -$941K | N/A | -$1.9M | N/A | -$1.2M | N/A | -$509K |
| EPS (Diluted) | $-0.37 | $-14.21 | N/A | $-4.90 | N/A | $-3.53 | N/A | N/A |
bblgw Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.4M+64.5% | $3.9M+3.3% | $3.7M-24.9% | $5.0M-41.4% | $8.5M+63.3% | $5.2M-22.1% | $6.7M+12640.9% | $52K |
| Current Assets | $6.4M+64.5% | $3.9M+3.3% | $3.7M | N/A | $8.5M | N/A | N/A | N/A |
| Cash & Equivalents | $6.0M+81.9% | $3.3M+9.9% | $3.0M-32.0% | $4.5M-40.9% | $7.5M+49.0% | $5.1M-24.2% | $6.7M+197747.2% | $3K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $334K-11.5% | $378K-54.6% | $831K-29.7% | $1.2M-53.6% | $2.5M+218.7% | $799K+700.2% | $100K-99.3% | $15.2M |
| Current Liabilities | $334K-11.5% | $378K-54.6% | $831K-29.7% | $1.2M-53.6% | $2.5M | N/A | $100K | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.0M+72.7% | $3.5M+19.9% | $2.9M-23.4% | $3.8M-36.2% | $5.9M+35.1% | $4.4M-33.1% | $6.6M+143.5% | -$15.1M |
| Retained Earnings | -$87.4M-2.9% | -$85.0M-5.1% | -$80.9M-2.0% | -$79.4M-10.3% | -$72.0M+1.2% | -$72.9M-3.4% | -$70.5M-0.3% | -$70.3M |
bblgw Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$591K+56.3% | -$1.4M+32.9% | -$2.0M+21.0% | -$2.6M-31.0% | -$2.0M-393.5% | -$395K-111.5% | -$187K+32.7% | -$278K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $0-100.0% | $1.1M+87.9% | $592K | $0 | N/A | N/A | $6.9M+2378.7% | $277K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
bblgw Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -10.5%+12.6pp | -23.1% | N/A | -38.6% | N/A | -23.4% | N/A | -972.1% |
| Current Ratio | 19.00+8.8 | 10.22+5.7 | 4.50 | N/A | 3.33 | N/A | N/A | N/A |
| Debt-to-Equity | 0.06-0.1 | 0.11-0.2 | 0.29-0.0 | 0.31-0.1 | 0.43+0.2 | 0.18+0.2 | 0.02+1.0 | -1.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Bone Biologics profitable?
No, Bone Biologics (bblgw) reported a net income of -$4.1M in fiscal year 2024.
What is Bone Biologics's earnings per share (EPS)?
Bone Biologics (bblgw) reported diluted earnings per share of $-4.83 for fiscal year 2024. This represents a 85.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Bone Biologics's operating cash flow?
Bone Biologics (bblgw) generated -$4.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Bone Biologics's total assets?
Bone Biologics (bblgw) had $3.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Bone Biologics spend on research and development?
Bone Biologics (bblgw) invested $2.1M in research and development during fiscal year 2024.
How many shares does Bone Biologics have outstanding?
Bone Biologics (bblgw) had 492,417 shares outstanding as of fiscal year 2024.
What is Bone Biologics's current ratio?
Bone Biologics (bblgw) had a current ratio of 10.22 as of fiscal year 2024, which is generally considered healthy.
What is Bone Biologics's debt-to-equity ratio?
Bone Biologics (bblgw) had a debt-to-equity ratio of 0.11 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bone Biologics's return on assets (ROA)?
Bone Biologics (bblgw) had a return on assets of -106.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Bone Biologics's cash runway?
Based on fiscal year 2024 data, Bone Biologics (bblgw) had $3.3M in cash against an annual operating cash burn of $4.1M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bone Biologics's Piotroski F-Score?
Bone Biologics (bblgw) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bone Biologics's earnings high quality?
Bone Biologics (bblgw) has an earnings quality ratio of 1.00x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.